Boucherie Quentin, Gentile Gaëtan, Chalançon Coralie, Sciortino Vincent, Blin Olivier, Micallef Joëlle, Bonin-Guillaume Sylvie
aPharmacology and Pharmacovigilance Department, Marseille Public University Hospital System bAix-Marseille University, Timone Institute of Neurosciences, UMR 7289 CNRS Integrated Pharmacology and Clinical Interface cDepartment of General Medicine, Medical School of Aix-Marseille University dRegional Management of Medical Service of French Health Insurance System in Provence Alpes Côte d'Azur-Corse eDepartment of Geriatrics, Marseille Public University Hospital System, Marseille, France.
Int Clin Psychopharmacol. 2017 Jan;32(1):13-19. doi: 10.1097/YIC.0000000000000150.
The aim of this study was to assess the prevalence of long-term antipsychotic (AP) use in community-dwelling patients with dementia considering hospitalization periods as AP exposure or not. A retrospective study was carried out from 2009 to 2012 on a PACA-Alzheimer cohort (which included 31 963 patients in 2009 and 36 442 in 2012 from 5 million inhabitants). Three groups of patients were identified according to the longest exposure to APs without interruption: nonusers, short-term users (≤3 successive months without discontinuation), and long-term users. Sensitivity analyses on hospitalization periods were carried out. The percentage of patients with at least one AP dispensing was stable over the study period (25.6% in 2009 vs. 26.5% in 2012). In 2012, 27.6% were AP long-term users. This increased to 46.7% when hospitalization periods were counted as AP exposure. In comparison with nonusers, AP users took more benzodiazepines and antidepressants. Short-term users were men [odds ratio (OR)=1.2, 95% confidence interval (CI) (1.1-1.3)] older than 85 years old [OR=1.2, 95% CI (1.1-1.2)]. Long-term users were more exposed to benzodiazepines [OR=1.2, 95% CI (1.1-1.4)]. This study showed that long-term use of AP remained frequent in community-dwelling patients with dementia. It also showed that the prevalence of long-term users almost doubled when hospitalization periods were counted as AP exposure. This underlines the need to consider hospitalization periods when assessing medication exposure in populations with frequent periods of hospitalization.
本研究旨在评估社区居住的痴呆患者长期使用抗精神病药物(AP)的情况,同时考虑将住院时间视为AP暴露与否。对2009年至2012年的普罗旺斯-阿尔卑斯-蓝色海岸大区阿尔茨海默病队列进行了一项回顾性研究(该队列在2009年包括31963名患者,2012年包括来自500万居民中的36442名患者)。根据最长不间断使用AP的情况确定了三组患者:未使用者、短期使用者(连续≤3个月未停药)和长期使用者。对住院时间进行了敏感性分析。在研究期间,至少有一次AP配药的患者百分比保持稳定(2009年为25.6%,2012年为26.5%)。2012年,27.6%为AP长期使用者。当将住院时间计为AP暴露时,这一比例增至46.7%。与未使用者相比,AP使用者服用更多的苯二氮䓬类药物和抗抑郁药。短期使用者为85岁以上的男性[比值比(OR)=1.2,95%置信区间(CI)(1.1 - 1.3)]。长期使用者更多地使用苯二氮䓬类药物[OR=1.2,95% CI(1.1 - 1.4)]。本研究表明,社区居住的痴呆患者中AP的长期使用仍然很常见。研究还表明,当将住院时间计为AP暴露时,长期使用者的患病率几乎翻了一番。这突出了在评估住院频繁人群的药物暴露时考虑住院时间的必要性。